Clinical Trials Search Results | Moffitt

Disease Site

Keyword

Study Type

Medication

Therapy

Principal Investigator

NCT#

Study Phase

1

2

3

4

62 Clinical Trials Found

Order By

Clinical Trial 22002

A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS

Disease Site: Any Site, Liver, Lung, Other Digestive Organ, Pancreas, Small Intestine, Stomach

PI: Kim, Dae Won

Clinical Trial 22100

Disease Site: Multiple Myeloma

PI: Grajales-Cruz, Ariel

Clinical Trial 22713

Disease Site: Any Site

PI: Soyano Muller, Aixa

Clinical Trial 22305

Disease Site: Breast, Lung, Other Respiratory and Intrathoracic Organs

PI: Soyano Muller, Aixa

Clinical Trial 20494

A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy

Disease Site: Melanoma, skin

PI: Tarhini, Ahmad

Clinical Trial 22574

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Disease Site: Any Site, Melanoma, skin

PI: Tarhini, Ahmad

Clinical Trial 19319

InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Disease Site: Penis / penile cancer, Other Male Genital

PI: Spiess, Philippe

Clinical Trial 21681

Disease Site: Brain and Nervous System

PI: Vogelbaum, Michael

Clinical Trial 22086

A Phase II Study of CART-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Disease Site: Multiple Myeloma

PI: Freeman, Ciara

Clinical Trial 22279

A Phase 1a/b Open-Label Master Study of PF-07799544 as a Single-Agent and in Combination with Other Targeted Agents in Participants with Advanced Solid Tumors

Disease Site: Melanoma, skin

PI: Eroglu, Zeynep

Clinical Trial 90042

Disease Site: Multiple Myeloma

PI: Fernandez, Hugo

Clinical Trial 20413

Phase III Study Of Daratumumab/Rhuph20 (Nsc- 810307) + Lenalidomide Or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapy In Patients With Multiple Myeloma (MM) Using Minimal Residual Disease To Direct Therapy Duration (DRAMMATIC STUDY)

Disease Site: Multiple Myeloma

PI: Nishihori, Taiga